SNBR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Buy now for a short-term momentum/swing setup. The chart is in an improving uptrend (bullish MA stack and positive/expanding MACD), options positioning is call-heavy (bullish), and the news flow adds near-term visibility (Kelce equity stake + marketing). Upside is likely capped near resistance at 11.66 then 12.14; a clean break above 11.66 improves odds of a move toward ~12+. This is more of a tactical buy than a conviction long-term compounding story given the still-weak revenue trend.
Trend/price action: Despite today’s -1.34% dip to 11.19, the technical structure is bullish with SMA_5 > SMA_20 > SMA_200, suggesting an established upswing. Momentum: MACD histogram is positive (0.0609) and expanding, consistent with strengthening upside momentum; RSI_6 at 67.23 is near the upper end of neutral (not yet an extreme overbought reading). Levels: Pivot 10.893 is the key near-term line to hold; support at 10.125 then 9.651. Overhead resistance sits at R1 11.661 and R2 12.135—these are the most realistic short-term targets given current price. Probabilistic trend read: pattern analogs imply mildly positive next-day odds and modestly positive next-month bias.
Intellectia Proprietary Trading Signals Intellectia Proprietary Trading Signals
News-driven visibility: Travis Kelce becoming a minority shareholder and participating in marketing campaigns can boost brand attention and near-term sales traffic.
Analyst tone improving: Piper Sandler materially raised its price target to $12 and highlighted confidence in new CEO Linda Findley as an operational/strategic upgrade.
Technical backdrop: Bullish moving-average stack and positive MACD support follow-through attempts toward 11.66/12.14 resistance.
Top-line pressure: Latest reported quarter shows revenue down -19.63% YoY (demand/industry and execution headwinds still present).
Profitability still negative: Net income and EPS improved sharply YoY but remain losses (Net Income -39.79M; EPS -1.73), meaning the turnaround is not yet fully proven.
Event risk ahead: Next earnings (QDEC
on 2026-02-23 pre-market can dominate near-term price action and cap willingness to pay up ahead of the print.
Street stance still cautious overall: Both listed analyst notes maintain Neutral ratings (even with a higher PT), implying “not a clear fundamental buy” consensus.
Latest quarter provided: 2025/Q3. Revenue fell to $342.879M (down -19.63% YoY), indicating ongoing demand softness. Losses narrowed materially YoY: Net income improved to -$39.79M (up 1168.81% YoY) and EPS improved to -1.73 (up 1135.71% YoY), signaling cost/actions are helping versus a weak prior-year base. Gross margin slipped to 59.9% (down -1.53% YoY), which is a mild deterioration and suggests promotions/input costs/mix pressure. Overall: financial trend is “turnaround-in-progress” (better losses) but not yet a growth story (revenue still contracting).
Recent rating/target trend: Wall Street tone is neutral but improving on targets. UBS (2025-11-06) cut PT to $6 (Neutral), reflecting earlier pessimism; Piper Sandler (2026-01-16) raised PT sharply to $12 from $5 (Neutral) after positive CEO interactions, signaling rising confidence in leadership/strategy even if fundamentals still need to prove out. Pros view: management upgrade narrative + potential brand/marketing tailwinds + technical recovery. Cons view: revenue contraction and ongoing losses keep ratings at Neutral and limit upside expectations near the new $12 target. Influential/political trading: No recent congress trading data; insider and hedge fund trends are noted as Neutral with no significant recent activity.
